Stockscreener 앱 받기
0.74%
시간 외 거래:
전일 마감가:
$4.08
열려 있는:
$4.13
하루 거래량:
3.08M
Relative Volume:
0.58
시가총액:
$328.48M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.4695
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
-4.93%
1개월 성능:
-42.39%
6개월 성능:
-40.70%
1년 성능:
-35.51%
1일 변동 폭
$4.03
$4.2593
1주일 범위
$3.93
$4.29
52주 변동 폭
$2.90
$11.16
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
ALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.05 | 345.52M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Investors in Altimmune, Inc. (ALT) Warned of Potential Securities FraudContact Levi & Korsinsky Today - Newsfile
What drives Altimmune Inc. stock priceHigh-yield trading alerts - Autocar Professional
Is Altimmune Inc. a good long term investmentRapid market gains - jammulinksnews.com
(ALT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
ALT ALERT: Ongoing Investigation Into Altimmune, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Securities Litigation as a Strategic Tool: Lessons from Altimmune's Legal Challenges and the Role of the Schall Law Firm - AInvest
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Altimmune Inc. Stock Analysis and ForecastUnmatched market gains - jammulinksnews.com
What analysts say about Altimmune Inc. stockExceptional earning trajectories - jammulinksnews.com
Did Altimmune, Inc. (ALT) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Lost Investment in Altimmune, Inc. (ALT)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - WV News
Why Altimmune Inc. stock attracts strong analyst attentionHigh Yield Opportunities - beatles.ru
What makes Altimmune Inc. stock price move sharplyFree Smart Money Stock Analysis - Newser
How Altimmune Inc. stock performs during market volatilityTrending Stock Alert - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
OneDigital Investment Advisors LLC Sells 2,887 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Concurrent Investment Advisors LLC Purchases New Holdings in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune (NASDAQ:ALT) Upgraded to “Strong Sell” at The Goldman Sachs Group - Defense World
Altimmune (NASDAQ:ALT) Upgraded at The Goldman Sachs Group - Defense World
Pomerantz LLP investigates securities fraud claims in Altimmune's IMPACT Phase 2b trial. - AInvest
Altimmune (NASDAQ:ALT) Rating Increased to Strong Sell at The Goldman Sachs Group - Defense World
The Goldman Sachs Group Upgrades Altimmune (NASDAQ:ALT) to Strong Sell - Defense World
Altimmune (NASDAQ:ALT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World
JMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $15.00 - Defense World
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - TipRanks
Altimmune falls after Goldman resumes coverage with "sell", citing competition - TradingView
Citizens JMP lowers Altimmune stock price target to $15 on fibrosis miss - Investing.com Nigeria
Goldman Sachs downgrades Altimmune stock to Sell on pemvidutide concerns - Investing.com Canada
Altimmune Plunges 14.56% on Goldman Sachs Downgrade - AInvest
Altimmune resumed with a Sell at Goldman Sachs - TipRanks
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development - TipRanks
Altimmune enrolls first patient in ALD treatment trial By Investing.com - Investing.com South Africa
ATTENTION Altimmune, Inc. (ALT) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
How To Trade (ALT) - news.stocktradersdaily.com
Levi & Korsinsky Launches Fraud Investigation on Behalf of Altimmune, Inc. (ALT) Shareholders - ACCESS Newswire
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluati - GuruFocus
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) - The Manila Times
Altimmune, Inc. Enrolls First Patient in RESTORE Phase 2 Trial for Pemvidutide in Alcohol-Associated Liver Disease - Quiver Quantitative
Altimmune enrolls first patient in ALD treatment trial - Investing.com
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial - Insider Monkey
ALT ALERT: Levi & Korsinsky Investigates Altimmune, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
Lost Money on Altimmune, Inc.(ALT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):